Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $39.20

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYREGet Free Report) have been assigned a consensus recommendation of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $39.20.

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Spyre Therapeutics in a research report on Monday, December 11th. They set a “buy” rating and a $31.00 price objective for the company. Stifel Nicolaus raised their price target on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. BTIG Research began coverage on shares of Spyre Therapeutics in a report on Wednesday, December 20th. They issued a “buy” rating and a $32.00 price target for the company. Wells Fargo & Company upgraded shares of Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $12.00 to $35.00 in a report on Friday, March 1st. Finally, Guggenheim began coverage on shares of Spyre Therapeutics in a report on Monday, December 11th. They issued a “buy” rating and a $44.00 price target for the company.

Get Our Latest Analysis on SYRE

Spyre Therapeutics Stock Performance

Shares of NASDAQ SYRE opened at $34.31 on Friday. Spyre Therapeutics has a 52-week low of $2.66 and a 52-week high of $47.97. The company has a 50 day simple moving average of $31.12. The firm has a market cap of $138.96 million, a PE ratio of -0.46 and a beta of 2.88.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($1.80). On average, analysts expect that Spyre Therapeutics will post -2.36 EPS for the current year.

Spyre Therapeutics Company Profile

(Get Free Report

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Recommended Stories

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.